Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients with brain lining spread: drug shows promise

NCT ID NCT04563871

Completed Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 24, 2026 · Updated 19 times

Summary

This study tested the drug osimertinib in 73 adults with a specific type of lung cancer (EGFR mutation-positive) that had spread to the lining of the brain. The goal was to see if the drug could control the cancer and help patients live longer. Participants took one pill daily, and researchers measured how well the cancer responded and how long the response lasted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • ChungBuk National University Hospital

    Cheonju, South Korea

  • National Cancer Center

    Goyang, South Korea

  • Samsung Medical Center

    Seoul, 135-710, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER (NSCLC)